Abstracts Archive - Page 22 of 2616 - ACR Meeting Abstracts

Abstract Number: 0290 • ACR Convergence 2025
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Ezgi Sahin¹, Omer Uludag², yasemin yalcinkaya³, Bahar Artim Esen⁴, Ahmet Gul³ and Murat Inanc³, ¹Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
Abstract Number: 0289 • ACR Convergence 2025
Standardized Interoperable Data Collection for Myositis Research: Developing Common Data Elements for Myositis Disease Activity Core Set Measures
Didem Saygin¹, Matthew Diller², Varsha Surampudi³, Mark Bodkin³, Payam Farhadi⁴, Adam Schiffenbauer⁵, Audrey Kessel³, Chris Mecoli⁶, Rohit Aggarwal⁷, Helene Alexanderson⁸, Michelle Best⁹, Olivier Benveniste¹⁰, Hector Chinoy¹¹, Brian Feldman¹², Linda Kobert¹³, Manuel Lubinus¹⁴, Liza McCann¹⁵, Chester V. Oddis¹⁶, Nicolino Ruperto¹⁷, Jens Schmidt¹⁸, Victoria Werth¹⁹, Christie Bartels²⁰, Hanna Kim²¹, Andrew Mammen²², Julie Paik²³, Ellen M. Werner¹³, Ingrid de Groot²⁴, Pedro Machado²⁵, Susan Kim²⁶, Tahseen Mozaffar²⁷, Adam M Huber²⁸, Angelo Ravelli²⁹, Richard Scheuermann² and Lisa Rider³⁰, ¹Rush University Medical Center, Chicago, IL, ²National Library of Medicine, National institutes of Health, Bethesda, MD, ³Social Scientific System Inc, a DLH holding company, Baltimore, MD, ⁴National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁵National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁸Karolinska University Hospital, Stockholm, Sweden, ⁹Cure JM Foundation, Lessburg, VA, ¹⁰Sorbonne Uniersite, Hopital de la Pitie-Salpetriere, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²The Hospital for Sick Children, Toronto, ON, Canada, ¹³The Myositis Association, Columbia, MD, ¹⁴Myositis Support and Understanding, Lincoln, DE, ¹⁵Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹⁶University of Pittsburgh, Pittsburgh, PA, ¹⁷Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ¹⁸Immanuel University Hospital Ruedersdorf, Brandenburg Medical School, Rudersdorf, Germany, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ²¹NIAMS, NIH, Bethesda, MD, ²²NIH, Bethesda, MD, ²³Johns Hopkins Rheumatology, Baltimore, MD, ²⁴The Myositis Association, Rotterdam, Netherlands, ²⁵University College London, London, United Kingdom, ²⁶UCSF Benioff Children's Hospital, San Francisco, CA, ²⁷University of California, Irvine, Orange, CA, ²⁸IWK Grace Health Centre, Halifax, NS, Canada, ²⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ³⁰National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD
Background/Purpose: Recent progress has been made in developing myositis outcome assessments, response and classification criteria, and consensus in the design and conduct of clinical trials…
Abstract Number: 0261 • ACR Convergence 2025
Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data
Daphne Guinn¹, Linchen He², Yuru Ren¹, Valeriy Korostyshevskiy¹ and Robert Beckman¹, ¹Georgetown University, Washington, ²Novartis, East Hanover
Background/Purpose: Basket trials group together participants who share a common biomarker or disease pathway across several diseases or phenotypes in a single clinical study. Such…
Abstract Number: 0151 • ACR Convergence 2025
Post-COVID Decline in Systemic Lupus Erythematosus Mortality in the United States: A National Analysis from 2014 to 2023
Ghassan Makhoul¹, Aziz-ur-Rahman Khalid², Islam Rajab¹, Hasan Munshi¹, Emmanuel Olumuyide³, MD Walid Akram Hussain¹, Aqsa Sorathia¹, Reshma John¹, Ahmed Huzien¹, ivan Mercado¹, Nargis Mateen⁴ and Robert Lahita², ¹St. Josephs University Medical Center, Paterson, ²St. Josephs University Medical Center, Wayne, NJ, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Paterson, NJ
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease with high morbidity and mortality. The impact of the COVID-19 pandemic on SLE-related deaths…
Abstract Number: 0130 • ACR Convergence 2025
Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome
Koshy Nithin Thomas¹, Pratibha Singh², Anu Balakrishnan³, Amita Aggarwal⁴ and Able Lawrence⁵, ¹Christian Medical College, Vellore, Tamil Nadu, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Antiphospholipid antibody syndrome (APS) is a common cause for acquired thrombophilia. The group termed ‘seronegative’ APS has not made any headway in the revised…
Abstract Number: 0152 • ACR Convergence 2025
Exploring internet use and health information behaviour in patients with inflammatory rheumatic musculoskeletal diseases (RMD)
Ioana Andreica¹, Sulafa Chikh Mohamad², Dieter Wiek³, Birgit Barten³, Iulia Roman⁴, Anja Kremser⁵, David Kiefer⁶, Philipp Sewerin¹, Uta Kiltz⁷ and Xenofon Baraliakos⁷, ¹Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, ³Deutsche Rheuma Liga, Germany, Bonn, ⁴Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Digital health literacy has recently become a focus of patient-centred recommendations, not only as a key social determinant of health, but also as a…
Abstract Number: 0149 • ACR Convergence 2025
Effect Of Osteoporosis And Opioid Use On Mortality And Unplanned Healthcare Utilization Among Patients With Rheumatoid Arthritis
Viengneesee Thao, Molly Moore Jeffery, Nafisseh Warner and Elena myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have a 2-fold increase in risk for osteoporosis compared to the general population. About 30-50% of RA patients experience…
Abstract Number: 0164 • ACR Convergence 2025
Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases
Iazsmin Ventura¹, Tamiko Katsumoto², Natasha Powell³, Elena Adams⁴ and Olivia Casey⁵, ¹Section of Rheumatology, University of Chicago, Chicago, ²Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ³University of Chicago Pritzker School of Medicine, Chicago, ⁴New Rochelle High School, New Rochelle, ⁵Autoimmune Association, Eastpointe
Background/Purpose: The impact of climate change on autoimmune and rheumatic diseases remains poorly understood. However, emerging evidence suggests extreme weather events, often related to climate…
Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Jheel Bhatt¹, Elizabeth Sloan², Selcan Demir³, Mojca Avramovic⁴, Seza Özen⁵, Doruk Erkan⁶ and Tadej Avcin⁷, ¹Advent Health Orlando, Orlando, FL, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Eskisehir Osmangazi University, Eskişehir, Turkey, ⁴University Children's Hospital, Ljubljana, Slovenia, ⁵Hacettepe University Medical Faculty, Ankara, Turkey, ⁶Hospital for Special Surgery, New York, NY, ⁷University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Jacqueline Madison¹, Elizabeth Sloan², Cristina Saez³, Olivia Kwan⁴, Kevin Lewis¹, Jonathan Marilao⁵, Blake Baay⁶, Rasha Elrefai⁴, Marissa Dale⁷, Deborah McCurdy⁸, Jheel Bhatt⁹, Sasidhar Goteti¹⁰, Ekemini Ogbu¹¹, Jason S. Knight¹ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Children's Hospital Colorado, Glendale, CO, ⁴Baylor College of Medicine, Houston, TX, ⁵University of Texas Southwestern, Dallas, TX, ⁶Scottish Rite for Children, Dallas, TX, ⁷Hospital for Special Surgery/NYP Cornell, New York, NY, ⁸UCLA Medical Center, Los Angeles, CA, ⁹Advent Health Orlando, Orlando, FL, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…
Abstract Number: 0285 • ACR Convergence 2025
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
Connor Buechler¹, Nawang Singhe², Lindsey Wanberg², Cody Rasner², Joseph McGrath², Karen Baker-James², Rebecca Freese² and David Pearson³, ¹University of Minnesota, Mendota Heights, MN, ²University of Minnesota, Minneapolis, MN, ³Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…
Abstract Number: 0269 • ACR Convergence 2025
Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group
Paula García-Escudero¹, Marta López², Berta Magallares³, Dolly Viviana Fiallo Suárez⁴, Diego Dios Santos⁵, César Antonio Egües Dubuc⁶, Santos Castañeda⁷, Alicia Garcia⁸, Isla Morante Bolado⁹, Elena María Oliver García¹⁰, Clara Garcia Belando¹¹, Cristina Corrales¹², Francisco Javier Toyos¹³, Judit Font-Urgelles¹⁴, Meritxell Salles Lizarzaburu¹⁵, Carolina Merino¹⁶, Irene Carrion¹⁷, Jose Angel Hernandez¹⁸, Lourdes Villalobos¹⁹, Alina-Lucica Boteanu²⁰, Beatriz Frade Sosa²¹, cristiana Sieiro²², Irene Monjo Henry²³, Ernesto Trallero²⁴, Eugenia Enriquez²⁵, Maria Rodriguez²⁶, Elena Riera Alonso²⁷, Marta Ibañez²⁸, Delia Reina²⁹, Rafael Benito Melero González³⁰, Giuliano Boselli³¹, Alberto Mariano³², Ignacio Vázquez Gómez³³, Jose Alberto Miranda³⁴, Clara Moriano³⁵, Elena Aurrecoechea³⁶, Paloma Vela Casasempere³⁷, Iñigo Rúa-Figueroa³⁸ and Jaime Calvo³⁹, ¹Hospital Universitario Álava, Bilbao, Spain, ²Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ³Hospital de Sant Pau, Bareclona, ⁴H.U. Doctor Negrín, Gran Canarias, ⁵C. H. U. A Coruña, A Coruña, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ⁷Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁸Rheumatologist, La Laguna, Spain, ⁹Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ¹⁰H.C. U. Lozano Blesa, Zaragoza, ¹¹H.C. U. Virgen de la arrizaca, Murcia, ¹²HOSPITAL UNIVERSITARIO MARQUES DE VALDECILLA, Santander, Spain, ¹³Virgen Macarena University Hospital,, Sevilla, Spain, ¹⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁵Rheumatology Department, Althaia Xarxa Assistencial Universitària Manresa Manresa (Spain)., Manresa, Spain, ¹⁶Rheumatology department. Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Madrid, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran CanariaHospital, Spain, ¹⁹Ramon y Cajal Hospital, MADRID, Spain, ²⁰H.U. Ramón y Cajal, Madrid, Spain, ²¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²²Univrsity of Manchester, Manchester, United Kingdom, ²³Hospital Universitario La Paz, Madrid, Spain, ²⁴H. U. Vall d'Hebron, Barcelona, ²⁵Clínica Universidad de Navarra, Madrid, Spain, ²⁶H. Clínico San Carlos, Madrid, Spain, ²⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ²⁸Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰C. H. U. de Ourense, Ourense, ³¹Rheumatology Division, Hospital Universitario Miguel Servet , Zaragoza, Spain, Zaragoza, Aragon, Spain, ³²Virgen del Rocío University Hospital, Sevilla, Spain, ³³H.U. Doctor Peset, Valencia, ³⁴C. H. U. Lucus Augusti, Lugo, Spain, ³⁵Hospital León, LEON, Castilla y Leon, Spain, ³⁶H. Sierrallana, Santander, ³⁷Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ³⁸Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ³⁹Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain
Background/Purpose: VEXAS syndrome is a rare disease caused by somatic mutations in UBA1 gene. Different mutations in this gene appear to be associated with specific…
Abstract Number: 0247 • ACR Convergence 2025
Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis
Elizabeth Volkmann¹, Steven Nathan², Karen Coeytaux³, Yanni Fan⁴, Jill Curran³, Haikun Bao³, Kamila Sroka-Saidi⁵, Ann Chauffe⁶ and Jeffrey J Swigris⁷, ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²Inova Advanced Lung Disease and Transplant Program, Falls Church, VA, USA, Falls Church, ³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁴Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, CT, ⁵Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Center for Interstitial Lung Disease, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA, Denver
Background/Purpose: Nintedanib was approved in the US for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (progressive pulmonary fibrosis [PPF])…
Abstract Number: 0233 • ACR Convergence 2025
Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis
Godbless Ajenaghughrure¹, Sila Mateo Faxas², Gurjot Singh³, Nirys Mateo Faxas⁴, Kim Nguyen³, Nicole Tejeda⁵ and Kimberly Ramirez Bonetti⁶, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Good Samaritan Hospital, Cincinnati, OH, ³Trihealth Good Samaritan Hospital, Cincinnati, ⁴Independent Author, Santo Domingo, Dominican Republic, ⁵Independent Author, Cincinnati, ⁶Independent Author, cincinnati, OH
Background/Purpose: While both SGLT2 inhibitors and GLP-1 receptor agonists improve glycemic control in type 2 diabetes (T2D), their safety profiles, particularly regarding hypoglycemia and infection…
Abstract Number: 0231 • ACR Convergence 2025
A Quality Improvement Project to Explore the Implications of the 2020 ACR Gout Guideline Recommendations for HLA-B5801 Testing
Sarah Anstett¹, Brian Coburn², Carlos Garcia-Gonzalez³, Max Krall¹, Akash Gupta⁴, Riya Madan⁵, Stephanie Lee⁶, Tania Aguila¹, Adam Mayer⁷, Elise Breed², Preethi Thomas⁸, Nora Sandorfi¹, Anupama Shahane¹ and Rachel Dayno¹, ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Hospital of University of Pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania Medical Center, Philadelphia, PA, ⁶University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, ⁷University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁸UNIVERSITY OF PENNSYLVANIA, Conshohocken, PA
Background/Purpose: The presence of the HLA-B5801 allele increases the risk of life-threatening allopurinol hypersensitivity syndrome (AHS). The 2020 ACR gout management guidelines conditionally recommend HLA-B5801…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].